BC008-1A

Phase 1Biologic

SSichuan Luzhou Buchang Biopharmaceutical Co., Ltd.

BC008-1A is one of 85 biologic programs targeting Patients With Advanced Solid Tumors. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Patients With Advanced Solid TumorsRecruiting

GliomaRecruiting

Patients With Advanced Solid TumorsPhase 1

Recruiting

GliomaPhase 1

Recruiting

Competition

Competitive Landscape

249 competitors in Patients With Advanced Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

20 2

Eloxatin

Teva

Phase 2

9 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

23 4

Tecentriq

Roche

Phase 2

4 5

Camptosar

Pfizer

Phase 2

4 6

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

15 7

Trodelvy

Gilead

Phase 2

2 8

Erbitux

IImclone

Phase 2

10 9

Lazcluze

Johnson & Johnson

Phase 2

1 10

Tuoyi

CCoherus Oncology, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Glioma

NCT06773481

Q2 2027

Phase 1Recruiting

Patients With Advanced Solid Tumors

NCT06773507

Clinical

Trials by Indication[1]

Glioma1 trial

BC008-1A Injection for Recurrent CNS WHO G4 Glioma

Recruiting·SSichuan Luzhou Buchang Biopharmaceutical Co., Ltd.·Phase 1·NCT06773481·40 enrolled

Patients With Advanced Solid Tumors1 trial

Phase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors

Recruiting·SSichuan Luzhou Buchang Biopharmaceutical Co., Ltd.·Phase 1·NCT06773507·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for BC008-1A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BC008-1A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BC008-1A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: SSichuan Luzhou Buchang Biopharmaceutical Co., Ltd.

BC008-1A

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Trials by Indication[1]

Glioma1 trial

Patients With Advanced Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News